TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02666625

Intervention type: PROCEDURE
Intervention: saliva samples
Study: NCT02666625

Intervention type: PROCEDURE
Intervention: blood samples
Study: NCT01455636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Sanitizer
Description: The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Sanitizer
Description: The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Improved Micronutrient Powder
Description: A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.
Study: NCT00265538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient educational letter to engage provider in hypertension rx discussion
Description: Patients will receive a customized/tailored letter (education) including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s). All the intervention arms (A, B and C) receive the letter.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive (Arms B and C) and health educator phone call (Arm C)
Description: Patients may receive a financial incentive for discussing the intervention letter with their provider and 6 months copay reimbursement and/or the financial incentive discussion incentive, 6 months copay reimbursement as well as a phone call reminder 1-2 days prior to their primary care appt. The Financial incentive is part of both Arms B and C. The health educator phone call is only in Arm C.
Study: NCT00427609

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bicillin L-A
Description: Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicillin L-A
Description: Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks
Study: NCT04486092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Study: NCT04832997

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prostate biopsy systematic random prostate biopsy (TRUS-Bx) + eventual MRI-targeted biopsy (MRI-TBx) + eventual microUS-targeted (Micro-US-TBx)
Description: Patients with both positive mpMRI and Micro-US, defined as the presence of one or more lesions with PI-RADS \>= 3 and PRI-MUS \>= 3 respectively, will receive a 12-core TRUSBx in addiction to MRI-TBx and Micro-US-TBx. Patients with both negative mpMRI and Micro-US will receive a 12-core TRUSBx. Patients with only positive mpMRI will receive MRI-TBx and 12-core TRUSBx. Patients with only positive Micro-US-TBx will receive Micro-US-TBx and 12-core TRUSBx.
Study: NCT01157975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone will be taken at a dose of 30 mg for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be taken at a dose of 40 mg for up to 4 days
Study: NCT02249143

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP and room air
Description: Stable premature infants on CPAP and room air and meeting specific stability criteria will be randomized to stay on continuous positive airway pressure and room air for an additional two weeks or will be transitioned to room air alone.
Study: NCT01555528

Intervention type: DEVICE
Intervention: easypod™
Description: Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
Study: NCT03388411

Intervention type: DIAGNOSTIC_TEST
Intervention: Gut microbiome profiling
Description: Gut microbial profiling will be done with next-generation sequencing targeting bacterial 16s rRNA genes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gut microbiome profiling
Description: Gut microbial profiling will be done with next-generation sequencing targeting bacterial 16s rRNA genes.
Study: NCT02401828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Switch from combination antiretroviral therapy to dolutegravir monotherapy
Study: NCT01455636

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Improved Micronutrient Powder
Description: A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No hand sanitizer
Description: All family members will receive hand-hygiene education with Information, Education and Communication (IEC) materials including pictorial messages describing critical points for hand-hygiene.~No placebo for the hand sanitizers will be provided to families in Groups 3 and 4 because it would be unethical if families were to use an inactive hand-hygiene product as a substitute for routine hand-washing. Nevertheless, all groups will be instructed

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Micronutrient Powder
Description: I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No Micronutrient Powder
Description: I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.
Study: NCT01664728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
Study: NCT03572595

Intervention type: DIAGNOSTIC_TEST
Intervention: F-18 FDG-PET/CT
Description: imaging using Positron Emission Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients with colorectal cancer either for staging or suspecting recurrence

Intervention type: DIAGNOSTIC_TEST
Intervention: F-18 FDG-PET/CT
Description: imaging using Positron Emission Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients with colorectal cancer either for staging or suspecting recurrence
Study: NCT03111628

Intervention type: DRUG
Group type: OTHER
Intervention: Omalizumab
Description: omalizumab 300 mg every 4 weeks by subcutaneous injection
Study: NCT01920685

Intervention type: OTHER
Group type: OTHER
Intervention: Anxiety intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety intervention
Study: NCT00956670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03970915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body warmer
Description: The body warmer will be wrapped in a waterproof treatment field to avoid the risk of burns, 2 body warmer will be applied on the inguinal crease and 2 on the subclavicular fossa.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard warming procedure
Description: Warming only according to the standard procedure : survival blanket and heating in the emergency vehicle.
Study: NCT00956670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study of High Risk Factors
Description: Undergo lymphedema assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Laparoscopic Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Lymphadenectomy
Description: Undergo lymphadenectomy
Study: NCT02314546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xylocaine
Description: Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: Placebo - Control patients will receive intranasal saline.
Study: NCT02397629

Intervention type: OTHER
Intervention: This study has no intervention
Study: NCT01026935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open inguinal hernia repair
Description: Altogether 400 patients are randomized to receive an open mesh repair with either sutured light weight mesh (38g/m2) or with a non-sutured light weight polypropylene mesh that adheres to tissues with polylactic micro hooks
Study: NCT00333099

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Impact (R) Enteral Nutrition
Description: mucositis frequency, treatment tolerance
Study: NCT02599701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: A single dose Gabapentin 300mg at bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single placebo dose with the same physical characteristics of the active intervention.
Study: NCT03858673

Intervention type: PROCEDURE
Intervention: VTH via the Tsuzi method with residual uterine ligament ligation
Description: VTH via the Tsuzi method with residual uterine ligament ligation
Study: NCT02579070

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DFUPS
Description: The DFUPS device is a two-camera instrument for capturing images of feet.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DFUPS
Description: The DFUPS device is a two-camera instrument for capturing images of feet.
Study: NCT02394873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-DFU
Description: Dressing for second-degree burn wound.
Study: NCT05223946

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Radiometry
Description: The MWR 2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases. There were several works on identification of excess of microwave emission due to inflammatory, process, cancer and other disorders.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microwave Radiometry
Description: The MWR 2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases. There were several works on identification of excess of microwave emission due to inflammatory, process, cancer and other disorders.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCENAR-CHENS-01
Description: Percutaneous electroneurostimulation (TENS) using the Self Controlled Energy Neuro Adaptive Regulator SCENAR-CHENS-01 device (ZAO OKB RITM, Taganrog, Russia)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Combination Therapy
Description: ketoprofen, tolperisone, symptomatic slow-acting drugs in osteoarthritis - SYSADOA - (glucosamine + chondroitin sulfate )

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Traditional Combination Therapy
Description: ketoprofen, tolperisone, symptomatic slow-acting drugs in osteoarthritis - SYSADOA - (glucosamine + chondroitin sulfate )
Study: NCT03081520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective response MIT
Description: Examine acute affective responses during and after five sessions of endurance training with moderate intensity continuous training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective response HAIT
Description: Examine acute affective responses during and after five sessions of endurance training with high-intensity aerobic interval training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective response HIIT
Description: Examine acute affective responses during and after five sessions of endurance training with high-intensity sprint interval training
Study: NCT04199637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TVG
Description: Therapeutic video game
Study: NCT02536989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
Study: NCT01268735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubricating eyedrops containing hydroxypropyl-guar
Description: Eyedrops BID
Study: NCT00109343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: ProQuad™ (V221)
Description: 0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: ProQuad™ (V221)
Description: 0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: ProQuad™ (V221)
Description: 0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
Description: 0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
Description: 0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
Description: 0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine
Study: NCT01723059

Intervention type: DRUG
Group type: OTHER
Intervention: Standard Triple Therapy
Description: for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential Therapy
Description: total 10 days
Study: NCT02746861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Supported DSMS
Description: Phone, SMS/text, and smartphone-based intervention.
Study: NCT02536989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole
Description: receive intravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
Study: NCT03997955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial induction
Description: Myofascial induction in plantar fascia

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham myofascial induction
Description: Sham myofascial induction in plantar fascia
Study: NCT02212067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
Study: NCT02266017

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Coping Skills Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training
Study: NCT00480116

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted Hepatitis B vaccine Lot 1
Description: 20 µg, IM, month 0 and 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted Hepatitis B vaccine Lot 2
Description: 20µg, IM, month 0 and 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted Hep B vaccine Lot 3
Description: 20µg, IM, month 0 and 1
Study: NCT04233684

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: rapid urease test
Description: Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.~Pathologic test for H. pylori by H\&E stain and Giemsa stain Gold standard is a immunohistochemistry.
Study: NCT00870727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole oral product
Description: Minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
Study: NCT00333099

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: impact
Description: 1500 calories every day :~-5 days before the begining of the chemoradiotherapy and until the last day of the treatment
Study: NCT03381638

Intervention type: DEVICE
Intervention: Blink Reflexometer
Description: The device uses 5 light puffs of air to the side of the eye causing a blink reflex that is captured by the high-speed camera tracking the eyelids.
Study: NCT00870727

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo will be identical in size and appearance to study drug.
Study: NCT01881464

Intervention type: DEVICE
Intervention: Endopath from Itamar medical - FDA approved device.
Description: endothelial function assessment by Endopath device

Intervention type: DRUG
Intervention: Anti TNF Alfa.
Description: This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
Study: NCT00533442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: MMF 1 gm BID beginning 1st day postoperative day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Part of standard maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Part of standard maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Part of standard maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Part of standard maintenance
Study: NCT03186170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSA sperm selection
Description: The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
Study: NCT03186170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SSA sperm selection
Description: The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
Study: NCT01858077

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABSORB BVS™
Description: Bioresorbable scaffold
Study: NCT01544881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin Inhalation Powder
Description: Inhalation Powder using the Gen2C inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Acting Analog
Description: Subcutaneous Injection
Study: NCT00720278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.15% azelastine hydrochloride 1644 mcg daily
Description: 0.15% azelastine hydrochloride 1644 mcg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% azelastine hydrochloride 1096 mcg daily
Description: 0.1% azelastine hydrochloride 1096 mcg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mcg Placebo daily
Study: NCT03838432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steep Pulse Device
Description: Applying the steep pulse to treat the patients with Prostate cancer
Study: NCT04912076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BM41
Description: Subcutaneous injection of increasing doses of BM41

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections of placebo containing aluminium hydroxide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Alutard SQ Betula verrucosa
Description: Subcutaneous injections with increasing doses of Alutard according to cluster up-dosing scheme.
Study: NCT00968487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized Plasma
Description: Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at -18 °C (-0.4 °F) (or colder) within 6 hours of collection.
Study: NCT01858077

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE™
Description: Drug eluting metallic stent
Study: NCT03448237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: Speech therapy adapted to the child, at least 25 sessions over 9 months.